Position in NVO
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$977,837,453
+$267,322,141 QoQ
Shares Held
20,397,110
+5.5% QoQ
Ownership
0.461%
of shares outstanding
% of Portfolio
0.51%
of 13F equity value
Holder Rank
#1
of 1,348 holders
Holding Since
Mar 2026
2 quarters on record
Voting authority
Sole 96%
Shared 0%
None 4%
Common Shares in NVO Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Dodge & Cox holds $7,907,700,561 across 13 Drug Manufacturers - General names. NVO ranks #4 (12.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GILD |
Gilead Sciences, Inc.
|
23,677,567 | $2,991,423,814 | |
| 2 | GSK |
GSK plc
|
48,197,514 | $2,526,513,683 | |
| 3 | SNY |
Sanofi
|
28,088,274 | $1,198,245,768 | |
| 4 | NVO |
Novo Nordisk A S
This page
|
20,397,110 | $977,837,453 | |
| 5 | NVS |
Novartis AG
|
759,373 | $119,008,936 | |
| 6 | LLY |
ELI LILLY & Co
|
41,258 | $49,486,087 | |
| 7 | MRK |
Merck & Co., Inc.
|
135,750 | $17,443,875 | |
| 8 | AZN |
Astrazeneca PLC
|
55,949 | $10,609,049 |
All Filings in NVO
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $977,837,453 | 20,397,110 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $710,515,312 | 19,333,750 | Shares | Sole | 2026-05-14 | |
| No filing history on record for this holder in this stock. | ||||||